NEW YORK (GenomeWeb) – ERS Genomics has licensed its CRISPR-Cas9 genome editing technology to Danish non-profit research services firm Bioneer, the organizations said today.
Dublin-based ERS Genomics was founded to provide access to CRISPR-Cas9 intellectual property held by Emmanuelle Charpentier for applications other than human disease treatment. This CRISPR IP is shared between her, Jennifer Doudna and the University of California, and the University of Vienna, and is separate from genome editing patents held by the Broad Institute.
Under the terms of the deal, Bioneer — a subsidiary of the Technical University of Denmark that is unaffiliated with the South Korean company of the same name — will be able to use the technology to develop and commercialize CRISPR-edited cell-based disease models. Additional terms were not disclosed.
"Bioneer is working with both industry and academia to solve complex disease relevant questions by using advanced disease modelling," Bioneer CEO Lars Pedersen said in a statement. "The CRISPR-Cas9 tools will enable clients and collaborators to precisely tailor their preclinical modelling strategies to their specific needs for predictive in vitro models."
Other licensees of ERS Genomics' CRISPR-Cas9 technology include Lonza Pharma & Biotech, Thermo Fisher Scientific, and Axcelead Drug Discovery Partners.